These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 18043601)

  • 1. Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention.
    Klotz L
    Nat Clin Pract Urol; 2008 Jan; 5(1):2-3. PubMed ID: 18043601
    [No Abstract]   [Full Text] [Related]  

  • 2. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH; Nam RK
    Can J Urol; 2006 Feb; 13 Suppl 1():48-55. PubMed ID: 16526983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer.
    Klotz L
    Eur Urol; 2005 Jan; 47(1):16-21. PubMed ID: 15582244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.
    Klotz L
    Nat Clin Pract Urol; 2005 Mar; 2(3):136-42; quiz 1 p following 149. PubMed ID: 16474710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Active surveillance for favorable risk prostate cancer: rationale, risks, and results.
    Klotz L
    Urol Oncol; 2007; 25(6):505-9. PubMed ID: 18047961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance?
    Schmidt C
    J Natl Cancer Inst; 2010 Oct; 102(20):1533-5. PubMed ID: 20935269
    [No Abstract]   [Full Text] [Related]  

  • 7. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression.
    Dall'Era MA; Konety BR
    Nat Clin Pract Urol; 2008 May; 5(5):277-83. PubMed ID: 18285752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [What does "PSA recurrence mean? "Active surveillance" for all risk groups is an option].
    Hautmann R
    Urologe A; 2006 Oct; 45(10):1239. PubMed ID: 17006696
    [No Abstract]   [Full Text] [Related]  

  • 9. The current status of active surveillance for prostate cancer.
    Pan DL; Samavedi S; Eldefrawy A; Manoharan M
    Postgrad Med; 2012 May; 124(3):50-8. PubMed ID: 22691899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.
    Ercole B; Marietti SR; Fine J; Albertsen PC
    J Urol; 2008 Oct; 180(4):1336-9; discussion 1340-1. PubMed ID: 18707696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active surveillance for prostate cancer: has the time finally come?
    Aragon-Ching JB
    J Clin Oncol; 2010 Jun; 28(16):e265-6; author reply e267. PubMed ID: 20406916
    [No Abstract]   [Full Text] [Related]  

  • 12. Active surveillance for early-stage prostate cancer: defining the triggers for intervention.
    Whitson JM; Carroll PR
    J Clin Oncol; 2010 Jun; 28(17):2807-9. PubMed ID: 20439633
    [No Abstract]   [Full Text] [Related]  

  • 13. Limitations and use of PSA velocity in the diagnosis and characterization of prostate cancer.
    Smith AD; Phillips JL
    Nat Clin Pract Urol; 2007 Nov; 4(11):576-7. PubMed ID: 17895878
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-risk localized prostate cancer: are we ready to tell patients that active surveillance is the preferred option?
    Brewster SF
    BJU Int; 2008 Sep; 102(8):923-6. PubMed ID: 18647299
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: prostate-specific antigen kinetics in clinical decision-making during active surveillance for early prostate cancer--a review.
    Malavaud B
    Eur Urol; 2008 Sep; 54(3):515-6. PubMed ID: 18585850
    [No Abstract]   [Full Text] [Related]  

  • 16. Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?
    Klotz L
    Semin Radiat Oncol; 2008 Jan; 18(1):2-6. PubMed ID: 18082582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate specific antigen screening and active surveillance in the elderly.
    Konety BR
    J Urol; 2009 Apr; 181(4):1534-5. PubMed ID: 19230925
    [No Abstract]   [Full Text] [Related]  

  • 18. Active surveillance for favorable-risk prostate cancer: who, how and why?
    Klotz L
    Nat Clin Pract Oncol; 2007 Dec; 4(12):692-8. PubMed ID: 18037873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment on: Insignificant prostate cancer and active surveillance: from definition to clinical implications.
    Aus G
    Eur Urol; 2009 Jun; 55(6):1331. PubMed ID: 19286303
    [No Abstract]   [Full Text] [Related]  

  • 20. Staging saturation biopsy in patients with prostate cancer on active surveillance protocol.
    Abouassaly R; Lane BR; Jones JS
    Urology; 2008 Apr; 71(4):573-7. PubMed ID: 18387385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.